Pharma Focus Asia

Merck Invests US$29 million (€28 million) to Open Drug Manufacturing Sites in Germany


Merck plans to invest US$29 million (€28 million) to open two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.


The new manufacturing facilities will offer a comprehensive solution for every critical facet of mRNA development, production, and market deployment, encompassing not only the creation of mRNA products but also their rigorous testing.

This encompasses specialised analytical development and biosafety testing explicitly tailored for mRNA technologies, ensuring the highest quality and safety standards are met.

These state-of-the-art facilities play a crucial role in an ongoing investment programme designed at advancing mRNA technologies. In addition, this will also generate 75 new employment opportunities. This integrated approach simplifies processes and reduces complexities.


Name   Merck
Type   New Facility
Budget US$29 million (€28 million)

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference